|1.||Witjes, J Alfred: 9 articles (10/2014 - 03/2005)|
|2.||Hillemanns, Peter: 7 articles (04/2015 - 03/2008)|
|3.||Grossman, H Barton: 7 articles (10/2014 - 07/2007)|
|4.||Stenzl, Arnulf: 7 articles (07/2014 - 12/2009)|
|5.||Peng, Qian: 7 articles (06/2014 - 12/2005)|
|6.||Jocham, Dieter: 7 articles (11/2013 - 07/2003)|
|7.||Shahzidi, Susan: 6 articles (10/2013 - 12/2005)|
|8.||Soergel, Philipp: 5 articles (08/2014 - 03/2008)|
|9.||Zaak, Dirk: 5 articles (07/2014 - 12/2009)|
|10.||Fradet, Yves: 5 articles (11/2013 - 07/2007)|
|1.||Urinary Bladder Neoplasms (Bladder Cancer)
07/01/2012 - "Hexaminolevulinate fluorescence cystoscopy significantly improves long-term bladder cancer time to recurrence with a trend toward improved bladder preservation."
04/01/2013 - "Hexaminolevulinate hydrochloride may be cost effective when used at first TURB for patients with suspected new or recurrent non-muscle invasive bladder cancer."
11/01/2014 - "Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology."
11/01/2010 - "We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates. "
09/01/2005 - "Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study."
04/01/2015 - "Photodynamic diagnosis after instillation of hexylaminolevulinate (Hexvix(®)) during transurethral resection of the bladder (TURB) helps in the detection of tumors and results in a reduction of recurrence. "
04/01/2013 - "Those patients who initially receive hexaminolevulinate hydrochloride blue light TURB also experience a lower overall cancer burden. "
12/01/2012 - "Photodynamic diagnosis with hexaminolevulinate helps to find tumors that could be missed by use of WLC only. "
11/01/2010 - "Hexaminolevulinate fluorescence cystoscopy significantly improves the detection of Ta and T1 lesions and significantly reduces the rate of tumor recurrence at 9 months."
04/01/2006 - "Hexaminolevulinate (HAL) is a diagnostic agent that allows the visualization of tumor tissue in the bladder by fluorescence cystoscopy. "
|3.||Carcinoma in Situ
11/01/2013 - "The hexyl aminolevulinate cystoscopy allows to identify a significantly greater number of lesions, including carcinoma in situ, compared to conventional white light cystoscopy. "
01/01/2004 - "Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy."
12/01/2012 - "Since then, PDD with intravesical application of 5-ALA or its ester hexaminolevulinate (Hexvix) has proven to be superior over standard white-light cystoscopy in detection of carcinoma in situ and dysplasia as well as enhancing margins of TCC. "
01/01/2010 - "To evaluate fluorescence cystoscopy with hexaminolevulinate (HAL) in the early detection of dysplasia (DYS) and carcinoma in situ (CIS) in select high risk patients. "
07/01/2007 - "Of a total of 113 carcinoma in situ lesions in 58 patients 104 (92%) were detected by hexaminolevulinate cystoscopy and 77 (68%) were detected by white light cystoscopy, while 5 were detected only on directed visually normal mucosal biopsy. "
|4.||Sarcoma (Soft Tissue Sarcoma)
09/01/2008 - "Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells."
09/01/2008 - "The role of multi-drug resistance (MDR1) and its product, P-glycoprotein (P-gp) on 5-aminolevulinic acid hexyl ester (Hexyl-ALA) mediated phototoxicity was determined with human uterine sarcoma cells, MES-SA control and MDR1 expressing MES-SA-Dx5. "
09/01/2012 - "This study employed a doxorubicin resistant (MES-SA-Dx5) human uterine sarcoma cell line and its counterpart (MES-SA), to elucidate the efficacy of aminolevulinic acid-hexylester (hexyl-ALA) mediated PDT at molecular and transcriptional levels. "
|5.||Cervical Intraepithelial Neoplasia
03/01/2008 - "The purpose of this study was to examine the pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate (HAL) in patients with cervical intraepithelial neoplasia (CIN). "
03/01/2008 - "Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia."
04/01/2015 - "A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2."
08/01/2014 - "Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia."
09/01/2011 - "Treatment of high grade cervical intraepithelial neoplasia by photodynamic therapy using hexylaminolevulinate may be costeffective compared to conisation procedures due to decreased pregnancy-related morbidity."
|5.||Aminolevulinic Acid (Levulan)
|6.||5-aminolevulinic acid hexyl ester
|8.||Apoptosis Inducing Factor
|9.||Lamin Type A (Lamin A)
|1.||Photochemotherapy (Photodynamic Therapy)